Print

PATH's Drug Development Program Announces Positive Phase 1 Results for Its Anti-Diarrheal Medication  
11/12/2012 10:00:59 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--PATH’s Drug Development program announced today the completion of two phase 1 clinical studies for iOWH032—its investigational new drug to treat acute secretory diarrhea caused by diseases such as cholera. The studies evaluated the drug’s safety and tolerability and measured the extent and rate of its absorption, distribution, metabolism, and excretion, reporting no serious adverse events. Based on these outcomes, iOWH032 will proceed into the next phase of clinical trials in Bangladesh in early 2013.
//-->